Where are shares of Jazz Pharmaceuticals PLC (JAZZ) falling in biotech after falling -1.20% this week?

A rating of 89 places Jazz Pharmaceuticals PLC (JAZZ) near the top of the biotech industry according to InvestorsObserver. Jazz Pharmaceuticals PLC’s score of 89 means it scores higher than 89% of industry stocks. Jazz Pharmaceuticals PLC also received an overall rating of 58, putting it above 58% of all stocks. Biotechnology is ranked 98th out of 148 industries.

JAZZ has an overall score of 58. Find out what this means for you and get the rest of the rankings on JAZZ!

What do these notes mean?

Finding the best stocks can be tricky. It is not easy to compare companies from one sector to another. Even companies that have relatively similar activities can sometimes be difficult to compare. InvestorsObserverThe tools allow for a top-down approach that lets you pick a metric, find the best sector and industry, and then find the best stocks in that sector. These rankings allow you to easily compare stocks and see what the strengths and weaknesses of a given company are. This allows you to find the stocks with the best short-term and long-term growth prospects in seconds. The combined score incorporates technical and fundamental analysis to provide a comprehensive view of a stock’s performance. Investors who then want to focus on analyst rankings or valuations can view separate scores for each section.

What’s going on with Jazz Pharmaceuticals PLC shares today?

Jazz Pharmaceuticals PLC (JAZZ) stock is trading at $139.21 at 1:55 p.m. on Friday, February 25, up $4.60, or 3.42% from the previous closing price of 134.61 $. The stock has traded between $134.27 and $139.71 so far today. Today, the volume is below average. So far, 231,672 shares have been traded with an average volume of 577,580 shares. Click here for the full Jazz Pharmaceuticals PLC stock report.

Stay in the know

Subscribe to our daily morning update newsletter and never miss market news, moves and more.

Thank you for signing up! You are ready to receive the Morning Update newsletter

Ada J. Kenney